Nonpharmacologic Interventions for Treatment-Resistant Depression in Adults
Background: Electroconvulsive Therapy
ECT involves passing an electric current through the brain to produce a convulsion. This is achieved through bifrontal/bilateral or unilateral electrode placement that uses millicoulombs of charge. ECT includes administration of anesthetic and muscle relaxants. ECT is usually performed 2 or 3 times a week for 3 to 4 weeks. ECT is FDA approved for the treatment of TRD and is widely available throughout the United States.
Keywords: FDA approval | duration | placement site | electroconvulsive therapy | ECT | availability | usual dosage
- Gaynes BN, Lux L, Lloyd S, et al. Nonpharmacologic Interventions for Treatment-Resistant Depression in Adults. Comparative Effectiveness Review No. 33 (Prepared by RTI International–University of North Carolina (RTI-UNC) Evidence-based Practice Center under Contract No. 290-02-0016-I). Rockville, MD: Agency for Healthcare Research and Quality; September 2011. AHRQ Publication No. 11-EHC056-EF. Available at: http://www.effectivehealthcare.ahrq.gov/trd.cfm.
- Lisanby SH. Electroconvulsive therapy for depression. N Engl J Med 2007 Nov 8;357(19):1939-45. PMID: 17989386.
- Shapira B, Tubi N, Lerer B. Balancing speed of response to ECT in major depression and adverse cognitive effects: role of treatment schedule. J Ect 2000 Jun;16(2):97-109. PMID: 10868320.
Your slide tray is being processed.